With the rapid progress in cancer biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams and research programs leveraging molecular oncology, immunology and other emerging fields. To address the national shortage of surgical investigators focused on surgical oncology, the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center has dedicated its T32 training program to producing academic surgical oncologists. The long-term objective is to train surgical residents and surgical oncology fellows in the essential research skills necessary to be productive independent surgical investigators in clinical, translational, and laboratory-based oncology research and to become leaders in oncology. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic surgical oncology, including minorities and women. Training is offered to eight postdoctoral M.D. or M.D. Ph.D. fellows either during a 24-month hiatus from general surgery residency training or during a three-year combined clinical/research fellowship in surgical oncology that begins after general surgery residency. Our T32 training program has been highly successful in achieving its goals and is now entering its 30th year. Upon completion of their residency training, most of our T32 research fellows either started fellowship training, or accepted academic surgical positions. Upon completion of their surgical oncology fellowship training, 100% of our T32 clinical/research fellows entered academic Surgical Oncology positions. Our T32 program provides research opportunities in a broad range of basic oncologic disciplines, in one of three training tracks; a. basic and translational research, b. quality, clinical effectiveness and outcomes, c. Clinical trials and biomarkers. This academic training program allows us to train surgeons with a diverse set of unique skills, increasing the likelihood of trainees obtaining an academic position upon completion of training. Training in biostatistics, responsible conduct of research, and a rich array of seminars and graduate courses available are integral to the T32 program. The T32 program faculty includes a multidisiplinary faculty pool, including established surgical investigators, medical and radiation oncologists as well as academic basic science researchers, with peer-reviewed funding. MD Anderson is a leading NCI-designated Comprehensive Cancer Center that provides trainees access to unique resources and our location in the Texas Medical Center provides our trainees potential collaborators at six academic institutions. Thus, the University of Texas MD Anderson Cancer Center is a highly stimulating environment for future leaders in academic surgical oncology.

Public Health Relevance

With the rapid progress in oncology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams as well as research programs leveraging molecular oncology, and new technologies. The goal of this T32 training program is to train surgical trainees in the essential research skills necessary to be productive independent surgical investigators and leaders in surgical oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA009599-30
Application #
9417548
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
1994-05-25
Project End
2023-01-31
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
30
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Hospitals
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kim, B J; Day, R W; Davis, C H et al. (2017) Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost 15:2158-2164
Roife, David; Kang, Ya'an; Wang, Li et al. (2017) Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161:1246-1254
Gall, Victor A; Philips, Anne V; Qiao, Na et al. (2017) Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res 77:5374-5383
Arango, Natalia Paez; Brusco, Lauren; Mills Shaw, Kenna R et al. (2017) A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8:41806-41814
Voss, Rachel K; Chiang, Yi-Ju; Torres, Keila E et al. (2017) Adherence to National Comprehensive Cancer Network Guidelines is Associated with Improved Survival for Patients with Stage 2A and Stages 2B and 3 Extremity and Superficial Trunk Soft Tissue Sarcoma. Ann Surg Oncol 24:3271-3278
Dai, Bingbing; Roife, David; Kang, Ya'an et al. (2017) Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 16:662-670
Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:
Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2017) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg :
Voss, Rachel K; Feng, Lei; Lee, Jeffrey E et al. (2017) Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab 102:2807-2813
Evans, Kurt W; Yuca, Erkan; Akcakanat, Argun et al. (2017) A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res 23:6468-6477

Showing the most recent 10 out of 177 publications